Paradoxical Lucidity in Severe End-Stage Dementia

Dementia Clinical Trial

Official title: Paradoxical Lucidity in Severe End-Stage Dementia

Status Recruiting

Clinical Trial Summary

Cognitive decline in dementia is considered irreversible, however episodes of paradoxical lucidity (PL) in severe dementia suggest other mechanisms may be in play. Beyond anecdotal reports of transient PL events occurring in patients predominantly in late-stage dementia and typically lasting anywhere from a few minutes to several hours, little is known about PL. The study team proposes to develop and conduct a mixed methods prospective study of PL during end stage advanced dementia, creating a definition and measurement scale for PL in advanced dementia, and identifying the potential electro cortical biomarkers of PL in advanced dementia. This study will be divided in two phases: Phase I and Phase II. During Phase I, the study team will collect sufficient and necessary data through an online survey and focus groups as well as assess the safety and feasibility of using symptom diaries (also known as daily trackers or journals) and real-time video EEG monitoring (vEEG). After preliminary review of the study procedures, the PI will decide whether to move onto the Phase II. The second phase will aim to expand the study population and refine study methods as well as create a definition and measurement scale for PL in advances dementia.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Dementia

• NCT number: NCT05234866
• Study type: Observational
• Source: NYU Langone Health
• Contact: Sam Parnia, MD, PhD
• Phone: (646)-501-6923
• Email: Sam.Parnia@nyulangone.org
• Status: Recruiting
• Start date: June 2, 2022
• Completion date: May 31, 2026